study of tumor samples from patients with lung cancer

Conditions: Lung Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this laboratory study is looking at tumor samples from patients with lung cancer.

objectives: primary * to determine the correlation between c-met expression, mutation and amplification, with stage and overall survival in patients with adenocarcinoma (ac) of the lung. secondary * to determine the correlation with epithelial mesenchymal transition (emt), egfr mutations and expression, kras mutations, p53 mutations, c-cbl protein expression, mutation, loss of heterozygosity (loh), dub3 expression \& regulation, and alk translocation, with respect to survival. * to determine the correlation with circulating c-met and hgf in ac and evaluate prognostic implications of circulating markers in ac of lung. * to determine (when available) levels of circulating met and hgf in serum before and after surgery. outline: this is a multicenter study. previously collected tissue samples from patients enrolled in calgb 140202 are assessed for mutation analysis of c-met, egfr, and k-ras. dna is examined by pcr, followed by agarose gel electrophoresis; gene amplification of c-met is examined by real time quantitative pcr; met/hf protein in serum is examined by elisa; and c-met, egfr, p53, c-cbl, dub3 enzyme, and alk, and epithelial mesenchymal transition examined by ihc.

Eligibility criteria:
inclusion criteria: * registration to cancer and leukemia group b (calgb) 140202 * institutional review board (irb) review and approval at the institution where the laboratory work will be performed is required * informed consent: the calgb does not require that a separate consent form be signed for this study * the subject population to be studied in this protocol includes patients selected from calgb 140202; all such patients have signed a written informed consent document meeting all federal, state, and institutional guidelines as part of entry into that trial * all samples to be studied were obtained and stored as part of calgb 140202; the material and data obtained from the patient's protocol record will be used to obtain appropriate clinical information; in no instance will the patient be contacted directly * there should be no physical, psychological, social, or legal risks associated with this study; no invasive procedures are recommended or requested * all appropriate and necessary procedures will be utilized to maintain confidentiality; all patients who have had samples submitted for analysis will have their calgb study number used to identify specimens * this study does not require direct patient contact and no specific risk or benefits to individuals involved in the trial are anticipated; it is likely, however, that the information gained will substantially help similar patients in the future

Keywords: adenocarcinoma of the lung recurrent non-small cell lung cancer stage 0 non-small cell lung cancer stage i non-small cell lung cancer stage ii non-small cell lung cancer stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer